ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -45 مورد

Clodronate (United States: Not available): Drug information

Clodronate (United States: Not available): Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Clodronate (United States: Not available): Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: Canada
  • Clasteon
Pharmacologic Category
  • Bisphosphonate Derivative
Dosing: Adult

Note: Consider a dental examination and appropriate preventative dentistry in patients with risk factors for osteonecrosis of the jaw (eg, cancer, chemotherapy, head and neck radiotherapy, corticosteroids, poor oral hygiene). Prior to clodronate treatment, promote renal excretion of excess calcium via restoration and maintenance of adequate fluid balance and urine output.

Breast cancer, early, adjuvant therapy

Breast cancer, early, adjuvant therapy (off-label use): Postmenopausal patients: Oral: 1,600 mg once daily for 2 to 3 years (Ref).

Hypercalcemia of malignancy

Hypercalcemia of malignancy (albumin-corrected serum calcium ≥12 mg/dL [≥3 mmol/L]) (alternative agent):

Note: May also be used at the same doses for treatment of hypercalcemia due to excessive bone resorption from other causes (eg, granulomatous diseases, hyperparathyroidism, vitamin D intoxication) (Ref). Asymptomatic or mildly symptomatic patients with chronic hypercalcemia may not require immediate treatment unless albumin-corrected serum calcium level is >14 mg/dL (>3.5 mmol/L) (Ref).

Oral: Usual dosage range: 1.6 to 2.4 g/day given in 1 or 2 divided doses; maximum dose: 3.2 g/day.

Re-treatment: Limited data suggest that patients who develop hypercalcemia following discontinuation of therapy or during oral therapy may be re-treated with oral therapy at a higher daily dosage (up to 3.2 g/day).

Osteolytic bone metastases

Osteolytic bone metastases: Note: Other bisphosphonates may be superior to clodronate in reducing skeletal complications related to multiple myeloma (Ref).

Oral: 1.6 to 2.4 g/day given in 1 or 2 divided doses; maximum dose: 3.2 g/day.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

SCr >5 mg/dL: Use is contraindicated.

SCr ≥2.5 to 5 mg/dL: There are no specific dosage adjustments provided in manufacturer's labeling; however, the manufacturer recommends considering a dose reduction or withholding therapy.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; however, elimination is predominantly renal.

Dosing: Adjustment for Toxicity: Adult

Femoral shaft fracture: Consider interrupting clodronate treatment pending a risk/benefit assessment.

GI mucosa irritation, new or worsening dyspepsia, dysphagia, retrosternal pain: Patients should seek prompt evaluation.

Hypocalcemia (in patients with osteolytic bone metastases): Interrupt the infusion or reduce the oral dose; correction of severe or symptomatic hypocalcemia may require calcium supplementation.

Ocular effects, complicated or severe: Complicated or severe ocular adverse events may require clodronate discontinuation and referral for ophthalmic evaluation.

Osteonecrosis of the jaw: Patients developing osteonecrosis of the jaw during therapy should receive care by an oral surgeon (Ref). Avoid invasive dental procedures and dental surgery during clodronate treatment if possible. For patients requiring dental procedures, the start of a new course of IV treatment should be delayed if there are unhealed open soft-tissue lesions in the mouth. For both IV and oral therapy, consider interrupting treatment until condition resolves and contributing risk factors are mitigated.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Endocrine & metabolic: Hypocalcemia (2%)

Gastrointestinal: Gastrointestinal signs and symptoms (<10%; including anorexia [1%], diarrhea [2%], nausea [3%], stomach pain, vomiting)

Renal: Increased serum creatinine (1%)

<1%: Hepatic: Increased serum alanine aminotransferase

Frequency not defined:

Endocrine & metabolic: Increased lactate dehydrogenase

Hematologic & oncologic: Myelodysplastic syndrome, myeloid leukemia

Hepatic: Increased serum alkaline phosphatase

Postmarketing:

Endocrine & metabolic: Increased parathyroid hormone

Gastrointestinal: Dysphagia, oral irritation

Genitourinary: Proteinuria

Hypersensitivity: Hypersensitivity reaction (including angioedema)

Neuromuscular & skeletal: Arthralgia (severe), myalgia (severe), ostealgia (severe)

Ophthalmic: Conjunctivitis, uveitis (Fietta 2003)

Renal: Nephrotoxicity

Respiratory: Oropharyngeal ulcer

Contraindications

Hypersensitivity to clodronate, other bisphosphonates, or any component of the formulation; severe GI tract inflammation; renal impairment (when serum creatinine >5 mg/dL, SI 440 micromole/L); pregnancy or breastfeeding.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority of cases have been reported in patients taking bisphosphonates.

• Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months.

• Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Strict adherence to dosing instructions is advised. Use with caution in patients unable to remain upright for ≥30 minutes after ingestion and/or with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition).

• Hyperparathyroidism: May cause a transient increase in plasma parathyroid hormone.

• Hypersensitivity: Hypersensitivity reactions including dyspnea or other respiratory disorders have been observed; use caution in patients with "aspirin triad" (bronchial asthma, aspirin intolerance, rhinitis).

• Hypocalcemia: Risk of hypocalcemia (often asymptomatic) due to chelation of serum calcium may occur with use.

• Hypophosphatemia: A transient decrease in phosphorus may occur with use.

• Ocular effects: Conjunctivitis, uveitis, scleritis, and episcleritis have been observed with bisphosphonates.

• Osteonecrosis of the external auditory canal: Long-term use of bisphosphonates has been associated with osteonecrosis of the external auditory canal; additional risk factors include steroid use, chemotherapy, infection, and trauma. Consider osteonecrosis of the external auditory canal in patients presenting with chronic ear infections.

• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include dental surgery, cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids), poor oral hygiene, and comorbid disorders (anemia, coagulopathy, infection, preexisting oral disease). According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy. Other risk factors for MRONJ include dentoalveolar surgery (eg, tooth extraction, dental implants), and preexisting inflammatory dental disease. Risk of MRONJ is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with intravenous antiresorptive use compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years (AAOMS [Ruggiero 2014]). The manufacturer’s labeling states that during therapy, invasive dental procedures and dental surgery should be avoided if possible; for patients requiring dental procedures, there are no data suggesting whether bisphosphonate discontinuation decreases ONJ risk; the start of a new course of IV treatment should be delayed if there are unhealed open soft-tissue lesions in the mouth; consider interrupting treatment until condition resolves and contributing risk factors are mitigated. The AAOMS authors suggest that, if conditions permit, therapy initiation of intravenous antiresorptive agents for cancer therapy should be delayed until optimal dental health is attained. In oncology patients already receiving intravenous bisphosphonates, dental procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).

Disease-related concerns:

• Bariatric surgery: Altered absorption and ulceration risk: Avoid oral bisphosphates after bariatric surgery; inadequate oral absorption and potential anastomotic ulceration may occur. If therapy is indicated, IV administered bisphosphonates are recommended.

Product Availability

Not available in the US

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Clasteon: 400 mg [contains corn starch, fd&c blue #2 (indigotine,indigo carmine)]

Administration: Adult

Oral: Swallow whole. Patient should be instructed to stay upright (not lie down) for at least 30 minutes after ingestion and until after the first food of the day (to reduce esophageal irritation). Administer with a glass of plain water at least 1 hour before or after food.

Use: Labeled Indications

Note: Not approved in the United States.

Hypercalcemia of malignancy: Management of hypercalcemia of malignancy.

Osteolytic bone metastases: Adjunct in the management of osteolysis due to bone metastases of malignant tumors.

Use: Off-Label: Adult

Breast cancer, early, adjuvant therapy

Medication Safety Issues
High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs (contraindicated in pregnancy) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Community/Ambulatory Care Settings).

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: May increase hypocalcemic effects of Bisphosphonate Derivatives. Aminoglycosides may increase nephrotoxic effects of Bisphosphonate Derivatives. Risk C: Monitor

Angiogenesis Inhibitors (Systemic): May increase adverse/toxic effects of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. Risk C: Monitor

Capecitabine: Bisphosphonate Derivatives may increase nephrotoxic effects of Capecitabine. Risk C: Monitor

Deferasirox: Bisphosphonate Derivatives may increase adverse/toxic effects of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor

Estramustine: Clodronate may increase serum concentration of Estramustine. Risk C: Monitor

Inhibitors of the Proton Pump (PPIs and PCABs): May decrease therapeutic effects of Bisphosphonate Derivatives. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: May increase adverse/toxic effects of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. Risk C: Monitor

Palopegteriparatide: Bisphosphonate Derivatives may decrease therapeutic effects of Palopegteriparatide. Bisphosphonate Derivatives may increase therapeutic effects of Palopegteriparatide. Risk C: Monitor

Polyvalent Cation Containing Products: May decrease serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Risk D: Consider Therapy Modification

Food Interactions

All food and beverages may interfere with absorption. Coadministration with dairy products may decrease absorption. Beverages (especially orange juice and coffee), food, and medications (eg, antacids, calcium, iron, and multivalent cations) may reduce the absorption of bisphosphonates as much as 60%. Management: Administer with a glass of plain water at least 2 hours (Bonefos) or 1 hour (Clasteon) before or after food.

Reproductive Considerations

Bisphosphonates are incorporated into the bone matrix and gradually released over time. Because exposure prior to pregnancy may theoretically increase the risk of fetal harm, most sources recommend discontinuing bisphosphonate therapy in patients who could become pregnant as early as possible prior to a planned pregnancy. Use in premenopausal patients should be reserved for special circumstances when rapid bone loss is occurring; a bisphosphonate with the shortest half-life should then be used (Bhalla 2010; Pereira 2012; Stathopoulos 2011).

Pregnancy Considerations

Use is contraindicated during pregnancy.

It is not known if bisphosphonates cross the placenta, but based on their lower molecular weight, fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).

Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by drug, dose, and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of bisphosphonate therapy (hypocalcemia, low birth weight, and decreased gestation have been observed in some case reports); however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Machairiotis 2019; Sokal 2019; Stathopoulos 2011). Exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).

Breastfeeding Considerations

It is not known if clodronate is present in breast milk.

Breastfeeding is contraindicated by the manufacturer.

Monitoring Parameters

Calcium and phosphate (periodically); SCr, BUN (in patients with known or suspected kidney impairment), CBC with differential, hepatic function. Monitor for signs/symptoms of GI mucosal irritation; hypersensitivity, hypocalcemia, ocular adverse effects; monitor for bone, joint, or muscle pain. Assess for atypical fracture in patients with thigh or groin pain.

Mechanism of Action

Clodronate is a bisphosphonate that lowers serum calcium by inhibition of bone resorption via actions on osteoclasts or on osteoclast precursors; may also have indirect inhibitory effects through osteoblastic cells, which control recruitment and activity of osteoclasts. In responding patients, clodronate inhibits osteoclastic activity and bone resorption by decreasing the flux of calcium from bone, thus reducing calcium levels in the blood.

Pharmacokinetics (Adult Data Unless Noted)

Duration of calcium-lowering effects: 5 days to 3 weeks following discontinuation.

Distribution: Vd: ~20 L; 20% of absorbed clodronate is bound to bone.

Bioavailability: 1% to 3%.

Half-life elimination: Mean: 5.6 hours.

Excretion: Clearance: 80 mL/minute.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Bonefos;
  • (AT) Austria: Bonefos | Lodronat;
  • (AU) Australia: Bonefos;
  • (BE) Belgium: Bonefos | Ostac;
  • (BG) Bulgaria: Bonefos | Ostac | Sindronat;
  • (BR) Brazil: Bonefos | Ostac;
  • (CH) Switzerland: Bonefos | Ostac | Ostac 520;
  • (CN) China: Bonefos | Clodronate disod. | Clodronic acid | De wei | Di gai na;
  • (CZ) Czech Republic: Bonefos | Lodronat;
  • (DE) Germany: Bonefos | Clodron 1a pharma | Clodron beta | Clodron hexal | Clodron Sandoz | Ostac;
  • (DO) Dominican Republic: Bonefos;
  • (EE) Estonia: Bonefos | Lodronat 520;
  • (EG) Egypt: Bonefos;
  • (ES) Spain: Bonefos | Mebonat;
  • (FI) Finland: Bonefos | Clodrobon;
  • (FR) France: Clasteon | Clastoban | Clodronate de Sodium G Gam | Lodronat | Lytos;
  • (GB) United Kingdom: Bonefos | Clasteon | Loron | Sodium clodronate;
  • (GR) Greece: Ostac;
  • (HK) Hong Kong: Bonefos | Ostac;
  • (HR) Croatia: Bonefos;
  • (HU) Hungary: Bonefos | Lodronat | Neogrand;
  • (ID) Indonesia: Actabone | Bonefos | Ostac;
  • (IE) Ireland: Bonefos | Loron;
  • (IL) Israel: Bonefos;
  • (IT) Italy: Acido clodronico sandoz | Clasteon | Climaclod | Clodron | Clody | Difosfonal | Moticlod | Niklod | Ossiten | Osteonorm | Soclonat;
  • (KR) Korea, Republic of: Ostac;
  • (LB) Lebanon: Bonefos;
  • (LT) Lithuania: Bonefos;
  • (LU) Luxembourg: Bonefos | Ostac;
  • (LV) Latvia: Bonefos;
  • (MX) Mexico: Bonefos | Fovaldron | Rolflegud;
  • (MY) Malaysia: Bonefos;
  • (NL) Netherlands: Bonefos | Ostac;
  • (NO) Norway: Bonefos | Ostac;
  • (NZ) New Zealand: Bonefos | Ostac;
  • (PH) Philippines: Bonefos;
  • (PK) Pakistan: Bonefos;
  • (PL) Poland: Bonefos | Clodran | Lodronat | Sindronat;
  • (PT) Portugal: Acido clodronico | Bonefos | Ostac;
  • (QA) Qatar: Clasteon;
  • (RO) Romania: Bonefos;
  • (RU) Russian Federation: Bonefos | Clobir;
  • (SE) Sweden: Bonefos | Ostac;
  • (SG) Singapore: Bonefos | Ostac;
  • (SI) Slovenia: Bonefos | Lodronat;
  • (SK) Slovakia: Bonefos | Lodronat | Sindronat;
  • (SR) Suriname: Bonefos;
  • (TH) Thailand: Bonefos;
  • (TN) Tunisia: Bonefos | Cledos;
  • (TR) Turkey: Bonefos;
  • (TW) Taiwan: Bonefos | Sinclote;
  • (UA) Ukraine: Bonefos | Sindronat;
  • (ZA) South Africa: Ostac
  1. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy. JADA. 2006;137(8):1144-1150. http://jada.ada.org/article/S0002-8177(14)64960-6/pdf [PubMed 16873332]
  2. Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(8):812-818. doi: 10.1200/JCO.2017.76.6402. [PubMed 29341831]
  3. Bhalla AK. Management of osteoporosis in a pre-menopausal woman. Best Pract Res Clin Rheumatol. 2010;24(3):313-327. [PubMed 20534366]
  4. Bonefos (clodronate disodium) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; March 2017.
  5. Clasteon (clodronate disodium) [product monograph]. Mississauga, Ontario, Canada: Sumitomo Pharma Canada Inc; October 2023.
  6. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30(12):1146-1148. [PubMed 19175968]
  7. Eisen A, Somerfield MR, Accordino MK, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol. 2022;40(7):787-800. doi:10.1200/JCO.21.02647 [PubMed 35041467]
  8. Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis. Ann Rheum Dis. 2003;62(4):378. doi:10.1136/ard.62.4.378 [PubMed 12634250]
  9. Gralow JR, Barlow WE, Paterson AHG, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst. 2020;112(7):698-707. doi:10.1093/jnci/djz215 [PubMed 31693129]
  10. Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm. 2014;71(23):2029-2036. [PubMed 25404594]
  11. Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44(3):428-430. [PubMed 19059370]
  12. Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig. 2019;40(2). doi:10.1515/hmbci-2019-0021 [PubMed 31539355]
  13. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723. doi:10.1136/bmj.h2723 [PubMed 26037642]
  14. O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474. doi: 10.1002/14651858.CD003474.pub4. [PubMed 29082518]
  15. Paterson AH, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734-742. doi: 10.1016/S1470-2045(12)70226-7. [PubMed 22704583]
  16. Pecherstorfer M, Schilling T, Janisch S, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med. 1993;34(7):1039-1044. [PubMed 8315476]
  17. Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012;52(4):580-593. [PubMed 22885424]
  18. Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031. [PubMed 25234529]
  19. Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol. 2006;2(1):7-14. doi:10.1200/JOP.2006.2.1.7 [PubMed 20871729]
  20. Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. J Clin Oncol. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148 [PubMed 31990618]
  21. Shane E. Treatment of hypercalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed August 17, 2022.
  22. Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int. 2019;30(1):221-229. [PubMed 30171300]
  23. Stathopoulos IP, Liakou CG, Katsalira A, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens). 2011;10(4):280-291. [PubMed 22281884]
Topic 8774 Version 178.0